ReviewJournal of psychiatry & neuroscience : JPN2026
The Eph-ephrin system in neuropsychiatric and neurodevelopmental disorders.
Review in Journal of psychiatry & neuroscience : JPN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin-producing hepatocellular (Eph) receptors are tyrosine kinase receptors that are canonically activated by their membrane tethered ligands, the ephrins. The Eph-ephrin system is critical in neurodevelopment, involved in processes such as neuronal growth and proliferation, axonal growth cone guidance, and cell survival. However, there is a significant knowledge gap in our understanding of the functional role of the Eph-ephrin system in later development, in both the adolescent and the adult brain. As various Eph receptor subtypes, and their associated ephrin ligands, are involved in the regulation of processes implicated in brain disorder pathogenesis, the Eph-ephrin system may represent an unexplored avenue for therapeutic target identification. Here, we will consolidate what is known about the Eph-ephrin system in synaptic plasticity, inflammation, and vascular permeability, linking the effects of specific ephrins and Eph receptors to depression and anxiety, autism, and schizophrenia. Novel insights into those Eph receptors with the most therapeutic promise will be provided and potential challenges of targeting these widely expressed receptor kinases discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.